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AbsTrACT
background The best strategy for controlling morbidity 
due to imported strongyloidiasis in migrants is unclear. 
We evaluate the cost- effectiveness of six possible 
interventions.
Methods We developed a stochastic Markov chain model. 
The target population was adult migrants from endemic 
countries to the European Union; the time horizon, a 
lifetime and the perspective, that of the health system. 
Average and incremental cost- effectiveness ratios (ACER 
and ICER) were calculated as 2016 EUR/life- year gained 
(LYG). Health interventions compared were: base case (no 
programme), primary care- based presumptive treatment 
(PCPresTr), primary care- based serological screening and 
treatment (PCSerTr), hospital- based presumptive treatment 
(HospPresTr), hospital- based serological screening and 
treatment (HospSerTr), hospital- based presumptive 
treatment of immunosuppressed (HospPresTrim) and 
hospital- based serological screening and treatment of the 
immunosuppressed (HospSerTrim). The willingness to pay 
threshold (WTP) was €32 126.95/LYG.
results The base case model yielded a loss of 2 
486 708.24 life- years and cost EUR 3 238 393. Other 
interventions showed the following: PCPresTr: 2 488 
095.47 life- years (Δ1 387.23LYG), cost: EUR 8 194 
563; ACER: EUR 3573/LYG; PCSerTr: 2 488 085.8 life- 
years (Δ1377.57LYG), cost: EUR 207 679 077, ACER: 
EUR 148 407/LYG; HospPresTr: 2 488 046.17 life- years 
(Δ1337.92LYG), cost: EUR 14 559 575; ACER: EUR 8462/
LYG; HospSerTr: 2 488 024.33 life- years (Δ1316.08LYG); 
cost: EUR 207 734 073; ACER: EUR 155 382/LYG; 
HospPresTrim: 2 488 093.93 life- years, cost: EUR 1 105 
483; ACER: EUR −1539/LYG (cost savings); HospSerTrim: 2 
488 073.8 life- years (Δ1365.55LYG), cost: EUR 4 274 239; 
ACER: EUR 759/LYG. One- way and probabilistic sensitivity 
analyses were undertaken; HospPresTrim remained below 
WTP for all parameters’ ranges and iterations.
Conclusion Presumptively treating all immunosuppressed 
migrants from areas with endemic Strongyloides would 
generate cost savings to the health system.
bACkground
Strongyloides stercoralis is an intestinal helminth 
that can cause strongyloidiasis, a parasitic 
disease in humans. While this nematode is 
most prevalent in the tropics and subtropics, 
its distribution is global, and it can also be 
found in temperate countries with favourable 
conditions.1
Some estimates suggest that at least 
370 million people are infected worldwide,2 
and a recent systematic review estimated a 
pooled prevalence of 12.2% (95% CI 9.0% 
to 15.9%) in migrants from endemic areas 
residing in non- endemic areas.3
Strongyloidiasis frequently presents asymp-
tomatically or with unspecific and mild 
clinical symptoms stemming from skin pene-
tration (rash, urticaria, larva currens), migra-
tion through the body (cough, sore throat, 
pulmonary infiltrates) and presence in the 
intestine (abdominal pain and diarrhoea).1 
key questions
What is already known?
 ► To date, no study has evaluated the cost- 
effectiveness of different strategies for screening 
and treating strongyloidiasis in people migrating 
from endemic countries to Europe.
What are the new findings?
 ► Presumptively treating immunosuppressed migrants 
from endemic areas, without screening or testing, 
was a cost- saving strategy compared with the cur-
rent base- case scenario.
What do the new findings imply?
 ► The results will have a direct impact on clinical 
guidelines and public health policy across Europe, 
allowing for cost savings.
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The most serious health risk is the development of dissem-
inated disease or hyperinfection syndrome, which usually 
occurs in immunosuppressed patients, particularly those 
using corticosteroids.4 However, many other conditions 
causing immunosuppression (such as leukaemia or trans-
plant) have also been associated with a severe form of the 
disease, with a reported mortality of up to 62%.5
Enhanced microscopic- based direct techniques, 
such as agar plate culture or the Baermann method, 
have improved diagnosis, but their sensitivity is still low 
because of the intermittent larval excretion and a low 
parasitic burden.4 Due to its accuracy, simplicity and 
reproducibility, serology is the most widespread and 
recommended technique used,4 having demonstrated 
a very high sensitivity, although the specificity is lower 
due to cross- reactions with other helminth infections. In 
terms of treatment, ivermectin is currently the drug of 
choice,6 with an optimal dosage schedule of a single dose 
for uncomplicated strongyloidiasis.7
Migrants from strongyloidiasis- endemic countries 
can import the disease to non- endemic areas. There, 
the disease may remain undetected for long periods of 
time due to lack of healthcare provider awareness, the 
unspecific presentation and the ability of the helminth to 
reproduce indefinitely in the host.8 If left untreated, the 
infection will be lifelong. In addition, the disease can be 
transmitted in non- endemic areas, for example, through 
solid organ transplantation.9
At the same time, in high- income countries or coun-
tries in economic transition, the increasing prevalence of 
chronic medical conditions and malignancies, combined 
with the availability of potentially harmful treatments, 
will likely increase the risk of severe complications from 
unrecognised chronic S. stercoralis infection in immuno-
suppressed patients.2 Routine screening for strongyloidi-
asis in migrants at high risk of exposure to Strongyloides 
infection and in immunosuppressed migrants at interme-
diate risk has been recommended as a strategy to prevent 
severe complications.10 11 However, several potential 
screening strategies could be implemented, so further 
cost- effectiveness studies are required to better under-
stand and implement the most cost- effective approach.
This study aims to evaluate the cost- effectiveness of 
six possible public health interventions to address and 
prevent strongyloidiasis in migrants from endemic areas 
living in the European Union (EU).
MeTHods
Target population setting and perspective
The target population of the study was migrants coming 
from S. stercoralis- endemic areas and living in non- endemic 
areas, specifically, migrants from South America, Central 
America, the Caribbean, Africa and Asia, and living in 
Europe. Although some EU countries are considered as 
endemic for S. stercoralis (such as Spain or Italy), the inci-
dence reported is very low and limited to certain popu-
lation subgroups. Thus, for the purpose of this study 
we considered all EU countries as non- endemic for the 
disease. The model was considered representative of the 
European setting, as the data used in the study originate 
from studies conducted in the region. Our analysis used 
a healthcare provider perspective.
strategies evaluated
Both hospital- based and primary care- based interventions 
were evaluated from a health system (provider) perspec-
tive. These interventions were agreed on by an internal 
panel as the most suitable strategies for potential imple-
mentation. Six strategies were evaluated against a base- 
case scenario where no specific intervention is under-
taken. This was considered the status quo, in which some 
cases can be detected through medical check- up when 
migrants present to the health centre for any reason. The 
evaluated interventions are as follows.
Primary care-based interventions
1. Primary care presumptive treatment (PCPresTr): pro-
viding presumptive treatment once at a primary care 
level to all migrants attended for any reason.
2. Primary care serology and treatment (PCSerTr): 
screening migrants at the primary care level with se-
rology and treating positive cases.
Hospital-based interventions
1. Hospital- based presumptive treatment (HospPresTr): 
providing presumptive treatment with ivermectin to 
migrants attended at hospital for any reason.
2. Hospital- based serology and treatment (HospSerTr): 
screening migrants at hospital clinic with serology and 
treating only the positive cases.
3. Hospital- based presumptive treatment of immuno-
suppressed migrants (HospPresTrim): providing pre-
sumptive treatment with ivermectin to immunosup-
pressed migrants at the hospital level (eg, migrants 
with an active tumour, starting steroids, HIV infected).
4. Hospital- based serology and treatment of immuno-
suppressed (HospPresTrim): screening of immuno-
suppressed migrants at the hospital level with serology 
and treatment of positive cases.
Cost-effectiveness model
A compartmental Markov model was considered appro-
priate to answer the study’s research question (figure 1). 
Due to the chronic nature of strongyloidiasis, a lifetime 
time horizon was chosen. A 3% yearly discount rate was 
applied to both costs and effectiveness.12
The model represents a cohort of 100,000 migrants 
aged 35 years from S. stercoralis- endemic countries. These 
individuals enter the model in one of two health states: 
infected or not infected with the disease. From there, 
infected migrants (state 1) can seek outpatient care (state 
2) and be diagnosed and treated (state 3). They can then 
be cured and go to the non- infected patient state (state 
4) or fail to achieve a cure and go back to the infected 
patient state (state 1). If infected migrants are not 
treated, they can develop disseminated strongyloidiasis 
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Figure 1 Compartmental Markov model for strongyloidiasis. No arrows to "death other cause" because patients from all 
states (except from death due to strongyloidiasis) can transition into this state; e1 is divided as patients that transition back 
from e2 cannot be treated or screened again; e4 is also divided as patients getting cured (ie, not infected) would not be tested 
or treated again.
and be admitted to hospital (state 7). Then they can be 
diagnosed and treated (state 8), achieving a cure (state 4) 
or dying (state 9). Non- infected migrants start at the non- 
infected state (state 4), can seek outpatient care (state 
5) and get diagnosed and treated as false positive cases 
(state 6) and go back to the not- infected state (state 4). 
The model was terminated when all individuals reached 
the death state.
Several assumptions were built into the model:
1. The composition of the migrant population did not 
change over time.
2. The percentage of immunosuppressed migrants was 
constant.
3. Migrants could never be treated twice for strongyloidi-
asis, nor was the outcome tested.
4. There is no local transmission.
5. The availability of ivermectin was guaranteed.
Online supplementary appendix 1 presents the details 
of the model as well as its parameters (online supple-
mentary material). The R code is available on reasonable 
request via email to the corresponding author.
Probabilities
The model parameters were obtained from direct 
measurements, systematic literature reviews and meta- 
analyses, and the Spanish Network for the Study of 
Infectious Diseases imported by Travellers and Migrants 
(+REDIVI).13 Expert opinions were used when no other 
sources were found in the literature.
Life-years gained
There are no appropriate estimates of disease- adjusted 
life- years (DALY) or quality- adjusted life- year (QALY) 
weights for S. stercoralis infection. Previous studies have 
estimated QALYs by making assumptions that were 
logical and insightful, but still arbitrary.14 15 Therefore, 
we used the objective measure of life- years gained (LYG) 
as the main outcome. With the model, the quantity of 
life- years for each strategy was calculated.
Costs
The cost estimates, sources, values, ranges and distribu-
tions are presented in online supplementary appendix 2 
(online supplementary material). We used the pricelist of 
the Hospital Clinic de Barcelona, the official published 
costs of the National Reference Laboratory from the 
Instituto de Salud Carlos III, and different insurance 
reimbursement lists (online supplementary appendix 
2). Adjustments were made to extrapolate costs to other 
European countries using purchasing power standards 
(PPS) (online supplementary appendix 2). Costs are 
presented as 2016 Euros (€).
Results are presented in terms of average and incre-
mental cost- effectiveness ratios (ACERs and ICERs), 
measured as 2016 EUR per LYG. A strategy was consid-
ered cost- effective if the ICER was lower than the Gross 
Domestic Product per capita of the European Union in 
2016 (EUR 32,127), the quantity selected as the willing-
ness to pay threshold (WTP) for this analysis .16
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Table 1 Base- case scenario probabilities
Probabilities Value and OWSA range PSA distribution Source




Beta (mean 0.001, SE 0.001) Valerio et al19




Beta (mean 0.92, SE 0.03) Bissofi et al28
Probability of clearing infection Baseline: 0.84
Range: 0.72- 0.98
Beta (mean 0.84, SE 0.066) Henriquez- Camacho 
et al6
Probability of seeking inpatient 
consultation due to severe disease
Baseline: 0.000423
Range: 0.000339–0.000508
Beta (mean 0.000423, SE 
0.0001)
Salvador et al21
Probability of being diagnosed and 
treated for severe disease
Baseline: 0.92
Range: 0.969–0.877
Beta (mean 0.92, SE 0.03) Bissofi et al28
Probability of curing and clearing 
infection in severe disease
1- CFR   CFR is estimated 
below




Beta (mean 0.47, SE 0.01) Buonfrate et al5
Probability of misdiagnosis and 
treatment for Strongyloides infection
Baseline: 0.001
Range: 0.0069–0.001
Beta (mean 0.001, SE 0.001) Bissofi et al28
Probability of death due to other causes Mortality tables   Spanish National 
Statistical Institute29
CFR, case fatality ratio; OWSA, one- way sensitivity analysis; PSA, probabilistic sensitivity analysis.
data analysis
The model was programmed in R software, V.3.4.2.17
Deterministic analysis was done with the most plausible 
value for each parameter. For each strategy, a one- way 
sensitivity analysis was undertaken, adjusting key parame-
ters one by one according to ranges of possible values to 
evaluate the impact on the ACER. A probabilistic sensi-
tivity analysis was also carried out: probability distribu-
tions were assigned to the model parameters to reflect 
uncertainty following guidelines.18 Because individual 
data were not available in most cases, the SD of each 
parameter was assumed to be 20% of the mean values 
(online supplementary appendix 2). Using 1000 Monte 
Carlo simulations, the ICER of the different iterations 
was plotted on a cost- effectiveness plane. The number of 
iterations to produce stable results was estimated by visual 
inspection of a graphic representation of the cumulative 
average net monetary benefits. Cost- effectiveness proba-
bility curves are also presented.
The study complied with the Consolidated Health 
Economic Evaluation Reporting Standards (online 
supplementary appendix 3, online supplementary 
material).
Patient and public involvement
No patients participated in the study.
role of the funding source
This manuscript is related to the project PI17/02020 
funded by the ISCIII and co- funded by the EU (FEDER). 
The team is partially supported by the Agència de 
Gestio’ d’Ajuts Universitaris i deRecerca (AGAUR) 
(2014SGR26) and by the Tropical Disease Cooperative 
Research Network (RD16/0027/0004) co- funded by the 
ISCIII and the EU (FEDER). The funder had no role in 
the study design, data collection, data analysis, data inter-
pretation or drafting of the report. All authors had full 
access to all study data and had final responsibility for the 
decision to submit for publication.
resuLTs
study parameters
Base- case transition probabilities are shown in table 1. 
The full list of probabilities, baseline values, sources, 
distributions and reasons of choice are shown in online 
supplementary appendix 1.
The prevalence of strongyloidiasis in migrants was 
considered to be 12.2% (95% CI 9.0% to 15.9%), based 
on a recent systematic review and meta- analysis.3 For the 
baseline scenario, the healthcare seeking rate was set 
at 1/10,000 person- years, as reported by Valerio et al.19 
For the interventions, we considered that the healthcare 
seeking rates reported in the Spanish national health 
inquiry were appropriate: for primary care, 0.78 (95% 
CI 0.76 to 0.80); and for hospital- based interventions, 
0.48 (95% CI 0.46 to 0.50).20 The probability of being 
diagnosed was based on the sensitivity of the test (92%). 
The same probability was considered among those who 
are potentially immunosuppressed since health inter-
ventions targeting those populations should be imple-
mented before the immunosuppression is established. 
The prevalence of immunosuppression was considered 
to be 2.7%.21 The annual probability of developing a 
severe condition (0.0423) was calculated by adapting the 
method by Freeman and Hutchison with data from the 
study by Salvador et al.21 22 To determine the effectiveness 
of the treatment with ivermectin, we used the results of 
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Figure 2 Cost- effectiveness plane representing the 
incremental costs in 2016 € Versus incremental effects in life- 
years gained (LYG). Hosp PresTr, hospital- based presumptive 
treatment; Hosp SerTr, hospital- based serology screening 
and treatment; HospPresTrImmuneSup, hospital- based 
presumptive treatment of immunosuppressed patients; 
HospSerTrImmuneSup, hospital- based serology screening 
and treatment of immunosuppressed patients; PC PresTr, 
presumptive treatment at a primary care setting; PCSerTr, 
serology screening and treatment at a primary care setting.
the Cochrane Review by Henriquez- Camacho et al.6 The 
schedule was chosen as a single dose, according to the 
results of a recent randomised clinical trial.7 The case 
fatality ratio of disseminated disease was considered to 
be 47% (range: 33%–62%).5 The mortality increase due 
to ivermectin in migrants from Loa loa endemic areas was 
11/10,000.29
Finally, pregnant women were not considered in the 
model since ivermectin has not been approved in this 
population.
base-case scenario results
The base- case scenario (ie, no programme established) 
produced a total of 2,486,708.24 life- years with a cost of 
EUR 3,238,393.
Primary care presumptive treatment
Treating every migrant presumptively in the primary care 
setting yielded a total of 2,488,095.47 life- years (increase 
of 1387.23 LYG) at a cost of EUR 8,194,563 (increase of 
EUR 4,956,170), for an ACER of EUR 3573/LYG.
Primary care serology and treatment
Screening every migrant at the primary care level and 
then treating only those with confirmed infections 
yielded a total of 2,488,085.82 life- years (increase of 
1377.57 LYG) at a cost of EUR 207,679,077 (increase of 
EUR 204,440,684). The ACER would be EUR 148,407/
LYG.
Hospital-based presumptive treatment
Treating every migrant presumptively in a hospital- based 
setting yielded a total of 2,488,046.17 life- years (Δ1337.92 
LYG) at total cost of EUR 14,559,575 (cost increase of 
EUR 11,321,182). The ACER would be EUR 8462/LYG.
Hospital-based serology and treatment
Hospital- based serology and treatment yielded a total 
of 2,488,024.33 life- years (ie, an increase of 1316.08 life- 
years) with a cost of EUR 207,734,073 and an ACER of 
EUR 1,155,382/LYG.
Hospital-based presumptive treatment of immunosuppressed
Presumptively treating only immunosuppressed migrants 
in the hospital setting yielded a total of 2,488,093.93 
life- years (increase of 1385.68 LYG) at a cost of EUR 
1,105,483, resulting in a total savings of EUR 2,132,910. 
As this strategy was found to be cost- saving, it had a nega-
tive ICER of EUR −1539/LYG.
Hospital-based serology and treatment of immunosuppressed
Screening immunosuppressed migrants and treating 
only those with confirmed infection in the hospital 
setting yielded a total of 2,488,073.8 life- years (Δ1365.55 
LYG), at a cost of EUR 4,274,239, for an ACER of EUR 
759/LYG.
Results of this deterministic analysis are represented 
in the cost- effectiveness plane in figure 2 and table 2. 
PCSerTr, HospPresTr, HospSerTr and HosptSerTrim 
interventions dominated. The most cost- effective strategy 
was HospPresTrim, which was actually cost saving (ICER 
EUR −1539). The next most efficient strategy was 
PCPresTr, but compared with HospPresTrim, the ICER 
was far from being cost- effective (ICER EUR 4,582,464/
LYG).
sensitivity analyses
To address parameter uncertainty, a one- way sensitivity 
analysis was carried out for each strategy evaluated 
(figure 3). The ICER of the HospPresTrim strategy 
remained below the cost- effectiveness threshold through 
the whole range of parameters.
A sensitivity analysis of structural uncertainty was 
undertaken, excluding the cost of the first visit in all 
intervention strategies based on the presumption that 
Strongyloides screening could be considered an opportu-
nistic intervention as part of a consultation sought by the 
migrant for another reason. Therefore, visit costs were 
not imputed to the programme costs. Moreover, some 
centres routinely screen migrants for imported diseases 
the first time they present for consultation, so serology 
would simply be added. In this analysis, the HospPre-
sTrim was the still most cost- effective strategy (ICER EUR 
−1461/LYG) (online supplementary appendix 4, online 
supplementary material).
A probabilistic sensitivity analysis was also carried out 
to evaluate overall uncertainty. Results are summarised 
in figure 4. The strategy with the highest probability of 
being cost- effective was HospPresTrim, with all iterations 
falling below the WTP.
As there is concern about the adverse effects that could 
occur when presumptive ivermectin is administered to 
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Table 2 Summary of the analysis results
LYG
Lifetime costs






Baseline 2,486,708.24 3,238,393 Baseline Baseline Baseline
HospSerTr 2,488,024.33 207,734,073 1316.08 204 495 681 Dominated
HospPresTr 2,488,046.17 14,559,575 1337.92 11 321 182 Dominated
HospSerTrIm 2,488,073.8 4,274,239 1365.55 1 035 846 Dominated
PCSerTr 2,488,085.82 207,679,077 1377.57 204 440 684 Dominated
HospPresTrIm 2,488,093.93 1,105,483 1385.68   −2,132,910* −1,539*
PCPresTr 2,488,095.47 8,194,563 1387.23 4 956 170 4,582,463.62
Dominated: the strategy is less effective and more costly.
*Cost saving.
HospPresTr, hospital- based presumptive treatment; HospPresTrIm, hospital- based presumptive treatment of immunosuppressed 
migrants; HospSerTr, hospital- based serology screening and treatment; HospSerTrIm, hospital- based serology screening and treatment of 
Immunosuppressed migrants; PCPresTr, presumptive treatment at a primary care setting; PCSerTr, serology screening and treatment at a 
primary care setting.
migrants infested with Loa loa (mainly severe encepha-
litis), a sensitivity analysis was undertaken allowing for 
a mortality increase in all migrants, as migrants from 
Loa loa- endemic countries may have a high presence 
in specific settings. Nevertheless, the ICER still showed 
cost savings (EUR −1617/LYG) (online supplementary 
appendix 3).
disCussion
Our results show that presumptively treating immuno-
suppressed migrants from Strongyloides- endemic countries 
was the most cost- effective strategy. In fact, it saved costs 
compared with current clinical practice. The rest of the 
strategies produced a gain in life- years but were not cost- 
effective using the chosen WTP or they were dominated 
(ie, they were less effective and more costly). Our find-
ings were robust to the ranges of parameter alterations 
undertaken both deterministically and probabilistically.
Previous studies have evaluated different strategies 
in refugees to the USA, concluding that the most cost- 
effective strategy was to perform presumptive treatment 
overseas.14 15 However, these studies evaluated only 
refugee populations in the USA, addressing mainly Asian 
populations, and the screening was not based on a sero-
logical test in a non- endemic setting. In our study, we 
decided to use serology as the only screening tool, as it 
is currently the most recommended strategy due to the 
low sensitivity of parasitological methods. In our model, 
we did not consider a lower sensitivity of the serolog-
ical test and a lower efficacy rate in immunosuppressed 
migrants,23 since under ideal conditions, a screening 
programme would be implemented before immunosup-
pression is established.
Given the uncertainty in some parameters of the model, 
we performed a sensitivity analysis. The parameters with 
the highest impact were the outpatient consultation costs 
and hospitalisation costs. Nevertheless, presumptively 
treating immunosuppressed migrants remained the most 
cost- effective strategy.
Importantly, the prevalence of strongyloidiasis did not 
alter the results of any of the strategies. This is a crucial 
issue since changes in migratory flows could also modify 
the scenarios contemplated in the near term. Dynamic 
models that consider demographic and migration flows 
could therefore be a reasonable strategy for adapting the 
results of this study to different contexts.
A major question regarding the implementation of a 
Strongyloides screening programme is whether the inter-
vention should target all migrants or just specific high- risk 
groups. Our results make it clear that immunosuppressed 
migrants should be the target population for this kind 
of programme. Ideally, they should be captured before 
immunosuppression is established. Thus, migrants that 
will be potentially immunosuppressed (ie, migrants diag-
nosed with a disease that is likely to need immunosup-
pressant drugs in the short or medium term, eg, steroids 
for chronic obstructive pulmonary disease or chemo-
therapy for lymphoma) should also be included.
Due to the heterogeneity of national health systems, 
the implementation of a presumptive programme 
in immunosuppressed and potentially immunosup-
pressed migrants could be done at different levels of 
care. Whereas for most national health systems, the 
strategy is only feasible as a hospital- based intervention, 
in settings with outstanding primary care programmes 
and trained health professionals, the strategy could be 
based in primary healthcare, where screening uptake is 
higher.24 Thus, emphasis must be placed on developing 
innovative and sustainable approaches to increasing the 
coverage of these programmes. For example, clinical 
decision- making tools may also be evaluated from a cost- 
effectiveness perspective.25
In addition, serological testing is not widely available 
in most clinical settings yet, which is a major drawback 
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Figure 3 Tornado plots of the one- way sensitivity analysis for each strategy evaluated. Red vertical line represents the 
deterministic value of the ACER. The black vertical line represents the cost- effectiveness threshold. ACER, average cost- 
effectiveness rate; CFR, case fatality ratio; LYG, life- years gained.
when considering serology screening- based strategies 
at both the hospital and primary care level. Developing 
point- of- care methods to diagnose strongyloidiasis 
would be highly desirable and could potentially change 
the scenario, making serological strategies more cost- 
effective. Nevertheless, a presumptive treatment strategy 
whose target population is exclusively migrants might not 
be acceptable and could even be perceived as discrim-
inatory, particularly since other screening plus treat-
ment strategies have also been shown to be cost- effective 
compared with the base- case scenario. HospSerTrim, 
HospPresTr and PCPresTr had ACERs that fell below the 
WTP, especially when the cost of the first visit was not 
imputed to the programme. Therefore, these interven-
tions could be considered as alternatives if other factors 
preclude HospPresTrim. PCPresTr would have the 
benefit of avoiding the risk of disseminated disease in 
migrants who become immunosuppressed in the future, 
as well as avoiding the theoretical reintroduction of local 
transmission.
An important novelty of our model is that we have 
accounted for excess mortality in individuals with concom-
itant Loa loa infection, as they have a higher mortality 
risk when treated with ivermectin.26 Nevertheless, this 
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Figure 4 Probabilistic sensitivity analysis. (A) The cost- effectiveness plane is represented. (B) Cost- effectiveness plane 
removing the two least cost- effective strategies. (C) Cost- effectiveness probability curves. Hosp PresTr, hospital- based 
presumptive treatment; Hosp SerTr, hospital- based serology screening and treatment; HospPresTrImmuneSup, hospital- 
based presumptive treatment of immunosuppressed patients; HospSerTrImmuneSup, hospital- based serology screening 
and treatment of immunosuppressed patients; PC PresTr, presumptive treatment at a primary care setting; PCSerTr, serology 
screening andtreatment at a primary care setting.
mortality increase is not very high (0.0011) Therefore, 
presumptive treatment did not have an important impact 
on LYG. However, when implementing this kind of 
programme in clinical practice, this potentially severe 
side effect should be avoided, particularly if Loa loa infec-
tion can be easily ruled out.
On the other hand, presumptive treatments cannot 
estimate cases and treatment failures of the drug, and 
ivermectin is not easily accessible in European coun-
tries. Therefore, implementing a presumptive treatment 
programme could entail supply side problems. This 
possibility should be evaluated locally. However, pharma-
ceutical companies and European regulatory bodies have 
recently launched initiatives to increase the production 
of ivermectin and market it in EU countries, and we hope 
these results will encourage such endeavours.
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Another major question is the kind of immunosuppres-
sion that poses the highest risk for severe strongyloidiasis. 
Further studies should evaluate and quantify the risk of 
progression to severe disease, depending on the level of 
immunosuppression. This knowledge would allow for a 
more targeted screening intervention, prioritising clin-
ical units or patients at high risk.
Our study has several limitations. The model has not 
been prospectively validated and relies on a series of 
assumptions. We did not account for the possibility of 
local transmission, as it was considered non- existent, 
with a highly unlikely risk for reintroduction. Some of 
the parameters used for the model have a high degree 
of uncertainty. Another limitation is that there are no 
estimates for DALYs in S. stercoralis infection. Therefore, 
we used the objective measure of LYG. Nevertheless, this 
parameter does not account for quality of life and imposes 
a limitation on the results of our study. While chronic 
Strongyloides infection is not considered to substantially 
reduce quality of life, very few good quality studies have 
been published so far on its clinical burden, so this is an 
issue that undoubtedly needs further investigation.27
ConCLusions
Presumptively treating for S. stercoralis infection in all 
immunosuppressed migrants from Strongyloides endemic 
countries seems to be a cost- saving strategy. Our findings 
provide an important basis to support the implementa-
tion of presumptive treatment programmes. However, 
other factors should also be considered, such as the 
heterogeneity of health system characteristics as well as 
the acceptability of this strategy, particularly in individ-
uals at higher risk of developing severe side effects.
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